NASDAQ · SCNX
Scienture Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SCNX: Nov 11, 2026
Scienture Holdings, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.5. The reported EPS for the same quarter last year was $-4.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Dec 2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Quiver Quantitative- Fintel · Oct 23, 4:14 AM EDTScienture Holdings Consensus Price Target Increased by 2,400% to $38.25The average one-year price target for Scienture Holdings (NASDAQCM:SCNX) has been revised to $38.25 / share, as of October 20, 2026. This is an increase of 2,400.00% from the prior estimate of $1.53 dated September 29, 2026. These figures represent aggregate analyst targets and d
- RTTNews · Sep 22, 9:26 AM EDTScienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal(RTTNews) – Scienture Holdings Inc. (SCNX) announced Tuesday that its subsidiary, Scienture, LLC, has entered into an agreement with a distribution partner to expand the commercial reach of REZENOPY Nasal Spray 10 mg to addiction treatment centers in the U.S.
- RTTNews · Jul 10, 2:10 AM EDTScienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up(RTTNews) – Scienture Holdings, Inc. (SCNX) announced that it has completed manufacturing of commercial launch inventory and will begin shipments in July of REZENOPY Nasal Spray 10 mg to U.S. pharmaceutical wholesalers, with broad availability expected in August.
- RTTNews · May 6, 11:37 AM EDTScienture Granted Third USPTO Patent For Arbli Oral Solution In Treating Hypertension(RTTNews) – Scienture Holdings Inc. (SCNX), a holding company for pharmaceutical companies, announced on Wednesday a third patent for the Arbli oral suspension or Losartan potassium in treating hypertension, granted by the U.S. patent and trademark office or USPTO.
- RTTNews · Mar 30, 11:50 AM EDTScienture Holdings Posts Strong Revenue Growth For 2025; Stock Down(RTTNews) – Scienture Holdings, Inc. (SCNX) reported its year-end 2025 financial results, highlighting significant revenue growth, improved gross margins and expanded commercial reach across its pharmaceutical portfolio.
- RTTNews · Mar 11, 10:45 AM EDTScienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray(RTTNews) – Shares of Scienture Holdings, Inc. (SCNX) are moving up about 31 percent on Wednesday morning trading after the company formalized multiple commercial Group Purchasing Organization agreements for REZENOPYTM (naloxone HCl) Nasal Spray 10 mg.
- Fintel · Feb 24, 3:03 PM ESTMaxim Group Initiates Coverage of Scienture Holdings (SCNX) with Buy RecommendationFintel reports that on February 24, 2026, Maxim Group initiated coverage of Scienture Holdings (NasdaqCM:SCNX) with a Buy recommendation. What is the Fund Sentiment?
- RTTNews · Jan 14, 10:23 AM ESTScienture And Summit's REZENOPY Awarded Orange Book-Listable Patent, Valid Till 2041(RTTNews) – Scienture Holdings, Inc.(SCNX) on Wednesday announced that the United States Patent and Trademark Office has issued an Orange Book-listable patent number covering REZENOPY or naloxone HCl Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5,
- RTTNews · Dec 23, 5:28 AM ESTScienture Prepares Launch Of REZENOPY, Its Highest-Strength Naloxone Nasal Spray(RTTNews) – Scienture Holdings Inc. (SCNX) announced an update on the upcoming commercial launch of REZENOPY, its FDA-approved 10 mg naloxone HCI nasal spray for emergency treatment of opioid overdose.
- RTTNews · Aug 14, 1:41 PM EDTScienture Secures $3.9 Mln Through Registered Direct Stock Offering(RTTNews) – Scienture Holdings, Inc. (SCNX), a holding company for specialty pharmaceutical businesses, has entered into a securities purchase agreement with institutional investors to sell 3,225,000 shares of common stock at $1.20 per share.
- Quiver Quantitative · Jul 24, 5:20 PM EDTScienture Holdings, Inc. Secures $3 Million Bridge Funding to Support Product Launches and Pipeline DevelopmentScienture Holdings, Inc. announced a $3 million bridge funding, securing $1.2 million to support product launches and development.
- Quiver Quantitative · Jul 16, 8:21 AM EDTScienture Holdings, Inc. Regains Compliance with Nasdaq Listing RequirementsScienture Holdings, Inc. announces compliance with Nasdaq Listing Rule 5550(a)(2) following stock price recovery.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Scienture Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.